Shares of ImmuPharma plc (LON:IMM – Get Free Report) rose 9.8% during mid-day trading on Wednesday . The company traded as high as GBX 3.75 and last traded at GBX 3.75. Approximately 879,750 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 2,526,928 shares. The stock had previously closed at GBX 3.41.
ImmuPharma Trading Up 9.8%
The stock has a 50-day simple moving average of GBX 3.97 and a 200 day simple moving average of GBX 4.90. The company has a market cap of £23.37 million, a price-to-earnings ratio of -10.12 and a beta of 3.01.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. As a group, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
- Photronics Is Quietly Becoming a Key Winner From the AI Boom
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
